Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
Saved in:
| Title: | Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome. |
|---|---|
| Authors: | Huls G; Department of Hematology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands. g.huls@umcg.nl., Chitu DA; Department of Hematology, Hemato Oncology Foundation for Adults in the Netherlands, Rotterdam, The Netherlands.; Department of Hematology, Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Tick L; Department of Hematology, Maxima Medical Center, Veldhoven, The Netherlands., Boersma R; Department of Hematology, Amphia Hospital, Breda, The Netherlands., Breems D; Department of Hematology, ZNA Stuivenberg/Middelheim, Antwerp, Belgium., Herbers A; Department of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Klein SK; Department of Hematology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands.; Department of Hematology, Meander Hospital Amersfoort, Amersfoort, The Netherlands., de Jonge S; Department of Hematology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Westerweel PE; Department of Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Cruijsen M; Department of Hematology, Catharine Hospital, Eindhoven, The Netherlands., Hoogendoorn M; Department of Hematology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Cuijpers M; Department of Hematology, Rijnstate Hospital, Arnhem, The Netherlands., Deeren D; Department of Hematology, AZ Delta Roeselare, Roeselare, Belgium., Bailly B; Department of Hematology, Hopital de Jolimont, Haine-Saint-Paul, Belgium., Visser O; Department of Hematology, Isala Hospital, Zwolle, The Netherlands., van Rhenen A; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands., Posthuma EFM; Department of Hematology, Reinier de Graaf Hospital, Delft, The Netherlands., Valk PJM; Department of Hematology, Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Cloos J; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Ammatuna E; Department of Hematology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands., Refos JM; Department of Hematology, Hemato Oncology Foundation for Adults in the Netherlands, Rotterdam, The Netherlands., Fakkert R; Department of Hematology, Hemato Oncology Foundation for Adults in the Netherlands, Rotterdam, The Netherlands., Löwenberg B; Department of Hematology, Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands. |
| Source: | Annals of hematology [Ann Hematol] 2025 Jan; Vol. 104 (1), pp. 361-368. Date of Electronic Publication: 2024 Oct 05. |
| Publication Type: | Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase II |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39367118 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Huls+G%22">Huls G</searchLink>; Department of Hematology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands. g.huls@umcg.nl.<br /><searchLink fieldCode="AU" term="%22Chitu+DA%22">Chitu DA</searchLink>; Department of Hematology, Hemato Oncology Foundation for Adults in the Netherlands, Rotterdam, The Netherlands.; Department of Hematology, Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Tick+L%22">Tick L</searchLink>; Department of Hematology, Maxima Medical Center, Veldhoven, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Boersma+R%22">Boersma R</searchLink>; Department of Hematology, Amphia Hospital, Breda, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Breems+D%22">Breems D</searchLink>; Department of Hematology, ZNA Stuivenberg/Middelheim, Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Herbers+A%22">Herbers A</searchLink>; Department of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Klein+SK%22">Klein SK</searchLink>; Department of Hematology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands.; Department of Hematology, Meander Hospital Amersfoort, Amersfoort, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Jonge+S%22">de Jonge S</searchLink>; Department of Hematology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Westerweel+PE%22">Westerweel PE</searchLink>; Department of Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Cruijsen+M%22">Cruijsen M</searchLink>; Department of Hematology, Catharine Hospital, Eindhoven, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hoogendoorn+M%22">Hoogendoorn M</searchLink>; Department of Hematology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Cuijpers+M%22">Cuijpers M</searchLink>; Department of Hematology, Rijnstate Hospital, Arnhem, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Deeren+D%22">Deeren D</searchLink>; Department of Hematology, AZ Delta Roeselare, Roeselare, Belgium.<br /><searchLink fieldCode="AU" term="%22Bailly+B%22">Bailly B</searchLink>; Department of Hematology, Hopital de Jolimont, Haine-Saint-Paul, Belgium.<br /><searchLink fieldCode="AU" term="%22Visser+O%22">Visser O</searchLink>; Department of Hematology, Isala Hospital, Zwolle, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Rhenen+A%22">van Rhenen A</searchLink>; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Posthuma+EFM%22">Posthuma EFM</searchLink>; Department of Hematology, Reinier de Graaf Hospital, Delft, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Valk+PJM%22">Valk PJM</searchLink>; Department of Hematology, Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Cloos+J%22">Cloos J</searchLink>; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Ammatuna+E%22">Ammatuna E</searchLink>; Department of Hematology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Refos+JM%22">Refos JM</searchLink>; Department of Hematology, Hemato Oncology Foundation for Adults in the Netherlands, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Fakkert+R%22">Fakkert R</searchLink>; Department of Hematology, Hemato Oncology Foundation for Adults in the Netherlands, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Löwenberg+B%22">Löwenberg B</searchLink>; Department of Hematology, Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Ossenkoppele+GJ%22">Ossenkoppele GJ</searchLink>; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229107334%22">Annals of hematology</searchLink> [Ann Hematol] 2025 Jan; Vol. 104 (1), pp. 361-368. <i>Date of Electronic Publication: </i>2024 Oct 05. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase II – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>9107334 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0584 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209395555%22">09395555 </searchLink><i>NLM ISO Abbreviation: </i>Ann Hematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39367118 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00277-024-06033-y Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 361 Titles: – TitleFull: Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Huls G – PersonEntity: Name: NameFull: Chitu DA – PersonEntity: Name: NameFull: Tick L – PersonEntity: Name: NameFull: Boersma R – PersonEntity: Name: NameFull: Breems D – PersonEntity: Name: NameFull: Herbers A – PersonEntity: Name: NameFull: Klein SK – PersonEntity: Name: NameFull: de Jonge S – PersonEntity: Name: NameFull: Westerweel PE – PersonEntity: Name: NameFull: Cruijsen M – PersonEntity: Name: NameFull: Hoogendoorn M – PersonEntity: Name: NameFull: Cuijpers M – PersonEntity: Name: NameFull: Deeren D – PersonEntity: Name: NameFull: Bailly B – PersonEntity: Name: NameFull: Visser O – PersonEntity: Name: NameFull: van Rhenen A – PersonEntity: Name: NameFull: Posthuma EFM – PersonEntity: Name: NameFull: Valk PJM – PersonEntity: Name: NameFull: Cloos J – PersonEntity: Name: NameFull: Ammatuna E – PersonEntity: Name: NameFull: Refos JM – PersonEntity: Name: NameFull: Fakkert R – PersonEntity: Name: NameFull: Löwenberg B – PersonEntity: Name: NameFull: Ossenkoppele GJ IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2025 Jan Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1432-0584 Numbering: – Type: volume Value: 104 – Type: issue Value: 1 Titles: – TitleFull: Annals of hematology Type: main |
| ResultId | 1 |
